Is pirfenidone (Asri) a hormonal drug and its pharmacological effects

Pirfenidone (Pirfenidone) is an oral anti-fibrotic drug used to treat idiopathic pulmonary fibrosis (IPF) and other lung diseases. It is not a hormonal drug, nor a glucocorticoid or steroid, but a small molecule anti-fibrotic drug. Unlike traditional hormonal drugs, the effect of pirfenidone does not rely on immunosuppression, but exerts its efficacy by inhibiting fibrosis-related signaling pathways and inflammatory factors.

Pirfenidone can inhibit the expression of fibrosis-mediating factors such as transforming growth factor-β (TGF-β), platelet-derived growth factor (PDGF), thereby reducing fibroblast proliferation and collagen deposition. By regulating these signaling pathways, pirfenidone can slow down the fibrosis process of lung tissue, maintain lung function, and delay the progression of the disease.

In addition to its anti-fibrotic effect, pirfenidone also has certain anti-inflammatory effects. It can inhibit the secretion of pro-inflammatory cytokines such as TNF-α and IL-1β, and reduce the inflammatory response of lung tissue. By combining anti-fibrosis and anti-inflammatory effects, pirfenidone can improve patients' respiratory symptoms and delay the decline of lung function to a certain extent.

In clinical applications, pirfenidone is used in the long-term management of patients with idiopathic pulmonary fibrosis to slow disease progression. Due to its non-hormonal nature, there will be no common adverse reactions of glucocorticoids such as osteoporosis or increased blood sugar, but it is still necessary to pay attention to potential side effects such as liver function monitoring and photosensitivity reactions. Patients should strictly follow medical instructions during use to ensure safety and efficacy.

Reference materials:https://www.drugs.com/